130 related articles for article (PubMed ID: 28546071)
21. Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
Sloderbach A; Hładoń B; Sochacki M; Kinas R; Kuśnierczyk H; Laskowska H
Pol J Pharmacol; 1997; 49(6):463-9. PubMed ID: 9566050
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide.
Sloderbach A; Hładoń B; Laskowska H
Acta Physiol Hung; 1996; 84(4):459-60. PubMed ID: 9328631
[TBL] [Abstract][Full Text] [Related]
23. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
24. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats.
Sener G; Sehirli O; Yegen BC; Cetinel S; Gedik N; Sakarcan A
J Pineal Res; 2004 Aug; 37(1):17-25. PubMed ID: 15230864
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Brüggemann SK; Kisro J; Wagner T
Cancer Res; 1997 Jul; 57(13):2676-80. PubMed ID: 9205076
[TBL] [Abstract][Full Text] [Related]
26. Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.
Kiewe P; Neumann M; Wagner T; Seyfert S; Albrecht H; Thiel E; Korfel A
Cancer Chemother Pharmacol; 2011 Jan; 67(1):27-33. PubMed ID: 20182727
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
[TBL] [Abstract][Full Text] [Related]
29. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
30. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
[TBL] [Abstract][Full Text] [Related]
31. Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography-tandem mass spectrometry.
Deroussent A; Rodriguez S; Martelli S; Seck A; Dubus-Daudigeos E; Desmaële D; Vassal G; Paci A
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Apr; 879(11-12):743-50. PubMed ID: 21377940
[TBL] [Abstract][Full Text] [Related]
32. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
Sancéau J; Poupon MF; Delattre O; Sastre-Garau X; Wietzerbin J
Oncogene; 2002 Oct; 21(50):7700-9. PubMed ID: 12400012
[TBL] [Abstract][Full Text] [Related]
33. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
[TBL] [Abstract][Full Text] [Related]
34. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
35. Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.
Nakata H; Miyazaki T; Iwasaki T; Nakamura A; Kidani T; Sakayama K; Masumoto J; Miura H
Oncol Rep; 2015 Apr; 33(4):1593-8. PubMed ID: 25633802
[TBL] [Abstract][Full Text] [Related]
36. Thermal enhancement of the effect of ifosfamide against a spontaneous murine fibrosarcoma, FSa-II.
Kuroda M; Urano M; Reynolds R
Int J Hyperthermia; 1997; 13(1):125-31. PubMed ID: 9024933
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide-induced nephrotoxicity: mechanism and prevention.
Nissim I; Horyn O; Daikhin Y; Nissim I; Luhovyy B; Phillips PC; Yudkoff M
Cancer Res; 2006 Aug; 66(15):7824-31. PubMed ID: 16885387
[TBL] [Abstract][Full Text] [Related]
38. Comparative activity of ifosfamide and cyclophosphamide.
Brade W; Seeber S; Herdrich K
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S1-9. PubMed ID: 3545522
[TBL] [Abstract][Full Text] [Related]
39. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
[TBL] [Abstract][Full Text] [Related]
40. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice.
Badary OA
J Ethnopharmacol; 1999 Nov; 67(2):135-42. PubMed ID: 10619376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
